# Where the Evidence Is Strongest

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/where-the-evidence-is-strongest

> Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.

## Key points

- MACE −16% and a composite kidney endpoint −21%, both at HIGH certainty by GRADE.
- Kidney failure −28%; albumin-to-creatinine ratio −26%; no excess acute kidney injury.
- Benefits held regardless of SGLT2 inhibitor use (interaction p=0.41), so the effects look additive, not redundant.
- Almost nothing else on this register reaches high certainty.
- The semaglutide SUCRA ranking is from an exploratory analysis and is the weakest number in the paper.

Most of the evidence we examine has something wrong with it: heterogeneity, confounding, exploratory subgroups, thresholds barely cleared. This one is different. In people with chronic kidney disease, a synthesis of 13 trials (97,428 participants, 31,846 of them with confirmed CKD) rates the cardiovascular and kidney benefits at **high certainty by GRADE**,[1] the top of the scale. We have not been able to write that on this site before.

## What the evidence shows

*GLP-1 receptor agonists in chronic kidney disease. 13 randomized trials, 31,846 participants with confirmed CKD.[1]*

| Outcome | Effect | Certainty |
| --- | --- | --- |
| Major adverse cardiovascular events | **16% reduction** (HR 0.84, 95% CI 0.79–0.89) | **High** |
| Composite kidney endpoint | **21% reduction** (HR 0.79, 0.73–0.86) | **High** |
| Kidney failure | 28% reduction (HR 0.72) | — |
| Urine albumin-to-creatinine ratio | 26% decrease | — |
| Acute kidney injury | **No excess risk** | — |

That last row matters more than it looks. The obvious mechanistic worry with these drugs in kidney disease is dehydration: vomiting and reduced fluid intake are exactly how someone with impaired kidneys ends up with acute injury. The concern is sensible, and it did not materialize.

## The question every CKD patient actually has

Many people with chronic kidney disease and type 2 diabetes now take an SGLT2 inhibitor, which has its own strong kidney evidence. What taking both means day to day is in [an SGLT2 and a GLP-1 together](https://glpwatchdog.org/research/sglt2-and-a-glp1-together). So the practical question is less whether a GLP-1 works than whether it adds anything *on top of what someone is already taking*.

> **The benefits held regardless of SGLT2 inhibitor background use, with an interaction P of 0.41.** That is the statistic we have used twice before to take apart apparent subgroup differences. Here it does its most useful job, showing that two treatments are additive rather than redundant.

That one number does a lot of work. We covered a case where an interaction P of .06 left a clean-looking split unestablished, in [the statistic that asks if groups differ](https://glpwatchdog.org/research/the-statistic-that-asks-if-groups-differ), and a mirror case where values of 0.62, 0.40 and 0.99 showed subgroups behaving alike, in [how many people to treat to help one](https://glpwatchdog.org/research/how-many-people-to-treat-to-help-one). Here the same test answers a question with money and inconvenience riding on it, and the answer is that the benefit holds on top of an SGLT2 inhibitor.

## What 'high certainty' means, and why it is unusual here

GRADE rates evidence on four levels (very low, low, moderate, high) based on risk of bias, consistency, directness, precision and publication bias. **High** means further research is very unlikely to change the estimate.

Almost nothing we have covered reaches it. The BMJ synthesis of 262 trials rated the newest drugs *very low to low*. The aspiration meta-analysis was *low*. The dose-withholding finding was *very low*. Set against that background, two high-certainty outcomes is a different kind of result.

> A review that only ever discounts evidence is as useless as one that only ever promotes it.

The reason this particular question is well answered is not luck. It was studied in dedicated randomized trials, in a defined population, against hard endpoints such as dialysis, transplantation and death, which are counted rather than measured on a scale. That is what produces high certainty, and it is what most questions in this field have not had.

## The one figure to hold loosely

> **Semaglutide ranked highest among the individual drugs, with a SUCRA of 78.4%.** SUCRA is a ranking statistic from network meta-analysis, roughly the probability a treatment is among the better options. Rankings of this kind are notoriously unstable, since small changes in the network reorder them, and the authors describe that analysis as exploratory.

The high-certainty finding is about the *class*. The ranking within it is not, and reading the SUCRA figure as “semaglutide is the best one for kidneys” would be taking the weakest number in the paper as its strongest.

For the trial that anchors this whole area, and the numbers needed to treat it produced, see [how many people to treat to help one](https://glpwatchdog.org/research/how-many-people-to-treat-to-help-one); for the broader kidney picture, [GLP-1s and your kidneys](https://glpwatchdog.org/research/glp1-and-your-kidneys).

## Frequently asked questions

### Do GLP-1 drugs protect the kidneys?

In chronic kidney disease, yes, with high-certainty evidence. Across 13 trials, they reduced major cardiovascular events by 16% and a composite kidney endpoint by 21%, with kidney failure risk down 28%.

### Does it help if I am already on an SGLT2 inhibitor?

The benefits held regardless of SGLT2 inhibitor background use, with an interaction P of 0.41, which means the two appear additive rather than redundant. That is the practical question for the many people with kidney disease who are already on one.

### Is there a risk of acute kidney injury?

No excess risk was observed. The concern is reasonable, since vomiting and reduced fluid intake are how impaired kidneys get injured, but it did not appear in these trials.

### What does high certainty mean?

On the GRADE scale it is the top of four levels, meaning further research is very unlikely to change the estimate. Almost nothing else covered on this site reaches it.

### Is semaglutide the best one for kidneys?

That ranking comes from an exploratory network analysis using a statistic whose orderings are notoriously unstable. The high-certainty finding is about the drug class; the ranking within it is the weakest number in the paper.

## References

1. Kaur R, Singh A. Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. 2026. PMID: 42337824. https://pubmed.ncbi.nlm.nih.gov/42337824/

---

Cite as: GLP Watchdog, Nora Bissett, "Where the Evidence Is Strongest", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/where-the-evidence-is-strongest

Canonical HTML page: https://glpwatchdog.org/research/where-the-evidence-is-strongest

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
